(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
13 March 2003 (13.03.2003)

PCT

(10) International Publication Number
WO 03/020282 A1

(51) International Patent Classification[7]: A61K 31/535, C07D 498/04, 498/16

(21) International Application Number: PCT/GB02/03903

(22) International Filing Date: 23 August 2002 (23.08.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

0121019.4	30 August 2001 (30.08.2001)	GB
0206031.7	14 March 2002 (14.03.2002)	GB

(71) Applicant *(for all designated States except US)*: **ALIZYME THERAPEUTICS LIMITED** [GB/GB]; Granta Park, Great Abington, Cambridgeshire CB1 6GX (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **HODSON, Harold, Francis** [GB/GB]; 69 Whitecroft Way, Beckenham, Kent BR3 3AW (GB). **DUNK, Christopher, Robert** [GB/GB]; Alizyme Therapeutics Limited, Granta Park, Great Abington, Cambridgeshire CB1 6GX (GB). **PALMER, Richard, Michael, John** [GB/GB]; Alizyme Therapeutics Limited, Granta Park, Great Abington, Cambridgeshire CB1 6GX (GB). **MITCHELL, Dale, Robert** [GB/GB]; BioFocus plc, Chesterford Park, Saffron Walden, Essex CB10 1XL (GB). **BIRAULT, Véronique** [FR/GB]; BioFocus plc, Chesterford Park, Saffron Walden, Essex CB10 1XL (GB). **HUNT, Russell, George** [GB/GB]; BioFocus plc, Chesterford Park, Saffron Walden, Essex CB10 1XL (GB).

(74) Agents: **CORNISH, Kristina, Victoria, Joy** et al.; Kilburn & Strode, 20 Red Lion Street, London WC1R 4PJ (GB).


(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: THIENO-(1,3)-OXAZIN-4-ONES WITH LIPASE INHIBITING ACTIVITY



(I)

(57) Abstract: The use of a compound comprising formula (I), or a salt, ester, amide or prodrug thereof in the treatment of obesity and related disorders. The invention also relates to novel compounds within formula (I), to processes for preparing them and pharmaceutical compositions containing them. In formula (I): A is an optionally substituted thienyl moiety, Y is O, S, or NR^2, R^1 is a branched or unbranched alkyl (optionally interrupted by one or more oxygen atoms), alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, arylalkyl, reduced arylalkyl, arylalkenyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, reduced aryl, reduced heteroaryl, reduced heteroarylalkyl or a substituted derivative of any of the foregoing groups and R^2 is hydrogen or a group as defined for R^1.

WO 03/020282 A1